(Reuters) - The Gabapentin GR medicine was tested against postherpetic neuralgia, or persistent pain caused by damage to nerves from the shingles, or herpes zoster, viral infection.
The primary goal of the Phase 3 trial, which enrolled 407 patients, was to reduce average daily pain scores. Patients daily received a total of 1800 milligrams of Gabapentin GR in one or two doses.
Read more at Reuters.com Hot Stocks News
The primary goal of the Phase 3 trial, which enrolled 407 patients, was to reduce average daily pain scores. Patients daily received a total of 1800 milligrams of Gabapentin GR in one or two doses.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment